2021
DOI: 10.1002/ams2.696
|View full text |Cite
|
Sign up to set email alerts
|

Acute ischemic stroke biomarkers: a new era with diagnostic promise?

Abstract: Stroke is considered as the first cause of neurological dysfunction and second cause of death worldwide. Recombinant tissue plasminogen activator is the only chemical treatment for ischemic stroke approved by the US Food and Drug Administration. It was the only standard of care for a long time with a very narrow therapeutic window, which usually ranges from 3 to 4.5 h of stroke onset; until 2015, when multiple trials demonstrated the benefit of mechanical thrombectomy during the first 6 h. In addition, recent … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 123 publications
(223 reference statements)
0
12
0
Order By: Relevance
“…erefore, finding simple and noninvasive biomarkers for early screening and diagnosis of cognitive impairment in DM patients with AS is of great significance to the clinical health management of DM patients. miRNA is a key regulatory molecule that plays an important role in the development and function of the nervous system [14]. is study mainly explored the relationship between the expression of miR-181c and miR-101 in peripheral blood and CI occurrence in patients with DM complicated with AS.…”
Section: Discussionmentioning
confidence: 99%
“…erefore, finding simple and noninvasive biomarkers for early screening and diagnosis of cognitive impairment in DM patients with AS is of great significance to the clinical health management of DM patients. miRNA is a key regulatory molecule that plays an important role in the development and function of the nervous system [14]. is study mainly explored the relationship between the expression of miR-181c and miR-101 in peripheral blood and CI occurrence in patients with DM complicated with AS.…”
Section: Discussionmentioning
confidence: 99%
“…Ischemic stroke is the leading cause of death and disability worldwide, and its incidence is expected to increase given aging of the global population (Paul and Candelario-Jalil, 2021). Diagnostic biomarkers have been used in the context of stroke diagnosis for decades (Bsat et al, 2021), although rapid assessment and management are essential for improving patient prognosis. Syndecan-1 is a major marker of glycocalyx degradation, levels of which are elevated in the peripheral plasma of affected patients.…”
Section: Discussionmentioning
confidence: 99%
“…The efficacy of intravenous thrombolysis treating stroke is highly dependent on the treatment time ( Ai et al, 2021 ). Initially, rt-PA was proven to be safe within 3 h after stroke; however, recent studies have extended this time window to 4.5 h ( Bsat et al, 2021 ). Most patients present outside this time-window and are not eligible for thrombolysis.…”
Section: Ischemic Strokementioning
confidence: 99%